Efficacy of Retreatments With Intravitreal Bevacizumab

NCT00406744 | Terminated Phase 3

• 1 other identifier: APEC-0012
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Choroidal neovascularization is a leading cause of visual loss in people older than 60 years and for its treatment there had been performed multicentric studies with Lucentis (Ranibizumab) with a significant improval of visual acuity. In our institution we evaluated efficacy of bevacizumab in several pathologies but we dont know what would be the results if we use the same dose several times. Our purpose was to determine the efficacy of bevacizumab for improve or stabilize visual acuity with two or more intravitreal inyections of bevacizumab.

Conditions

Age Related Macular Degeneration; Choroidal Neovascularization

Keywords

neovascularization

Outcome Measures

Primary Outcomes (1)

• Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram

Interventions

Intravitreal injection of Bevacizumab DRUG

Eligibility Criteria

• Age: 60 Years - 95 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \* Any visual acuity
• OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid.
• Active angiogram leakage

You may not qualify if:

• \* Basal Inflammatory disease
• Endoftalmitis history
• Lesions bigger than 5400 u or with scarring greater than 50% of lesion.

Sponsors & Collaborators

• Asociación para Evitar la Ceguera en México: lead

Study Sites (1)

Asociacion para Evitar la Ceguera en Mexico

Mexico City, Mexico City, 04030, Mexico

Location

MeSH Terms

Conditions

Macular Degeneration; Choroidal Neovascularization; Neovascularization, Pathologic

Condition Hierarchy (Ancestors)

Retinal Degeneration; Retinal Diseases; Eye Diseases; Choroid Diseases; Uveal Diseases; Metaplasia; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Veronica Kon-Jara, MD

  Asociación para Evitar la Ceguera en México

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: November 30, 2006
• First Posted: December 4, 2006
• Study Start: May 1, 2006
• Primary Completion: May 1, 2006
• Study Completion: November 1, 2006
• Last Updated: June 3, 2024

Record last verified: 2024-05

Locations

ME (1)